Sildenafil Citrate Tablet, Film Coated
Product Images NDC 43063-940

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Sildenafil Citrate (NDC 43063-940). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Pd-rx Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

43063940 Label (43063940)

Label for Sildenafil USP 100 mg tablets supplied by PD-Rx Pharmaceuticals, Inc. The label shows the product name, strength (100 mg), and package size of 10 tablets. It includes a warning to keep the product out of reach of children, reorder and lot numbers (Reorder #110811, Lot H19A25), and expiration date (12/2020). The label features the PD-Rx Pharmaceuticals logo and manufacturer information from Oklahoma City, OK.*

FDA Label Image

Chemical Structure

Chemical structure diagram of sildenafil, the active ingredient in Sildenafil Citrate 100 mg film-coated tablets by PD-Rx Pharmaceuticals, Inc.*

FDA Label Image

Figure 1

Line graph depicting the change in systolic blood pressure (mmHg) over 24 hours post dose. Two lines represent data for SILDENAFIL 100mg and placebo groups. The x-axis shows time after dose in hours, and the y-axis shows the change in systolic blood pressure.*

FDA Label Image

Figure 2

A line graph showing the change in systolic blood pressure (SBP) in mmHg over an 8-hour period postdose. Two lines represent treatments: Doxazosin plus Placebo and Doxazosin plus Sildenafil 25 mg. The graph displays blood pressure changes over time, with the Sildenafil combination generally showing a greater decrease in SBP than the placebo combination throughout the timeframe.*

FDA Label Image

Figure 3

A line graph showing change in systolic blood pressure (SBP) in mmHg over 8 hours postdose. It compares two treatment groups: Doxazosin plus placebo and Doxazosin plus Sildenafil 50 mg, with SBP changes plotted against time (hours).*

FDA Label Image

Figure 4

A line graph showing changes in blood pressure (mmHg) over time after dosing (hours). It compares the effects of Doxazosin combined with Sildenafil 100 mg versus Doxazosin with placebo, with separate lines representing each treatment across an 8-hour period.*

FDA Label Image

Figure 5

A line graph depicting the pharmacokinetic profile of a commercial tablet of Sildenafil Citrate, showing plasma concentrations in nanograms per milliliter (ng/ml) over a 24-hour period post dose. Concentrations peak sharply within the first 1-2 hours, then gradually decline over the following hours, approaching near baseline at 24 hours.*

FDA Label Image

Figure 6 1

A bar chart showing percentage of patients at endpoint grouped by baseline score categories (0 to 5). Each baseline score category has stacked bars corresponding to scores 0 through 5 with varying heights, illustrating distribution of patient scores at endpoint for Sildenafil Citrate 100 mg tablet treatment.*

FDA Label Image

Figure 6 2

A bar chart depicting the percentage of patients at endpoint by baseline score categories ranging from 0 to 5. The bars are grouped by score values with varying heights indicating the distribution of patient percentages across different baseline scores.*

FDA Label Image

Figure 7

A bar graph depicting the percentage of patients reporting improvement in a study comparing placebo and sildenafil citrate at doses of 25 mg, 50 mg, and 100 mg. The vertical axis shows percentage improvements from 0 to 100%, and the horizontal axis lists groups with sample sizes: placebo (24%), sildenafil citrate 25 mg (63%), 50 mg (74%), and 100 mg (82%).*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.